Responses to DNAJA1 (and other chaperone molecules) have also previously been described in CML patients by Greiner et al.22, using SEREX and a K562 cDNA library, where 3 of 10 CML patients tested but none of 19 untreated AML patients and none of 20 healthy volunteers had anti-DNAJA1 IgG responses. This evidence concerns the gene DNAJA1 and chronic myelogenous leukemia, BCR-ABL1 positive.